Evidence map›Paper›PMID 34103082›Full record

ArticleBMC research notes2021

Exiguobacterium sp. is endowed with antibiotic properties against Gram positive and negative bacteria.

Nicole T Cavanaugh, Anutthaman Parthasarathy, Narayan H Wong, KayLee K Steiner, Jonathan Chu, Joseph Adjei, André O Hudson

Open access · goldAbstract read
In one paragraph

Article in BMC research notes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Harnessing the seaweed holobiont: antibacterial and antioxidant lead compounds from epiphytic microbiota.International microbiology : the official journal of the Spanish Society for Microbiology · 2026
    Article
  2. Article
  3. Article
  4. Interaction ofFrontiers in pharmacology · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Nicole T CavanaughThomas H. Gosnell School of Life Sciences, Rochester Institute of Technology, 85 Lomb Memorial Drive, Rochester, NY, 14623, USA.
Anutthaman ParthasarathyThomas H. Gosnell School of Life Sciences, Rochester Institute of Technology, 85 Lomb Memorial Drive, Rochester, NY, 14623, USA.
Narayan H WongThomas H. Gosnell School of Life Sciences, Rochester Institute of Technology, 85 Lomb Memorial Drive, Rochester, NY, 14623, USA.
KayLee K SteinerThomas H. Gosnell School of Life Sciences, Rochester Institute of Technology, 85 Lomb Memorial Drive, Rochester, NY, 14623, USA.
Jonathan ChuThomas H. Gosnell School of Life Sciences, Rochester Institute of Technology, 85 Lomb Memorial Drive, Rochester, NY, 14623, USA.
Joseph AdjeiNational Technical Institute for the Deaf, Rochester Institute of Technology, 52 Lomb Memorial Drive, Rochester, NY, 14623, USA.
André O HudsonThomas H. Gosnell School of Life Sciences, Rochester Institute of Technology, 85 Lomb Memorial Drive, Rochester, NY, 14623, USA. aohsbi@rit.edu.ORCID http://orcid.org/0000-0001-5690-4322
Rochester Institute of Technology · US

Funding

Isolation, identification and characterization of potentially novel antibiotics from rhizospheric bacteria without detectable in vitro resistanceR15GM144862 · NIGMS · ROCHESTER INSTITUTE OF TECHNOLOGY · PI HUDSON, ANDRE O · 2021 to 2022
$544k
Genetic and structural analysis of L,L-diaminopimelate aminotransferase (DapL): An attractive target for the development of narrow-spectrum antibioticsR15GM120653 · NIGMS · ROCHESTER INSTITUTE OF TECHNOLOGY · PI HUDSON, ANDRE O · 2016 to 2017
$468k
NIGMS NIH HHS R15 GM120653NIGMS NIH HHS R15 GM144862NIGMS NIH HHS RG15GM120653
6 · The paper itself

Abstract

objectiveIn order to isolate and identify bacteria that produce potentially novel bactericidal/bacteriostatic compounds, two ponds on the campus of the Rochester Institute of Technology (RIT) were targeted as part of a bioprospecting effort.

resultsOne of the unique isolates, RIT 452 was identified as Exiguobacterium sp. and subjected to whole-genome sequencing. The genome was assembled and in silico analysis was performed to predict the secondary metabolite gene clusters, which suggested the potential of Exiguobacterium RIT452 for producing antibiotic compounds. Extracts of spent growth media of RIT452 were active in disc diffusion assays performed against four reference strains, two Gram-negative (E. coli ATCC 25922 and P. aeruginosa ATCC 27853) and two Gram-positive (B. subtilis BGSC 168 and S. aureus ATCC 25923). Differential extraction and liquid chromatography was used to fractionate the extracts. Efforts to identify and elucidate the structure of the active compound(s) are still ongoing.

Indexed as

Anti-Bacterial AgentsExiguobacteriumBacteriaEscherichia coliGram-Negative BacteriaMicrobial Sensitivity TestsStaphylococcus aureusAnti-Bacterial AgentsAntibiotic resistanceAntibioticsExiguobacteriumSecondary metaboliteWhole-genome sequencing

Identifiers

PMID34103082
PMCPMC8186047
OpenAlexW3167307155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.